The susceptibilities of 36 recent isolates of Staphylococcus aureus and 35 recent isolates ofStaphylococcus epidermidis were determined against each of 65 antimicrobial agents and against two of them in combination. Rifampin was the most active of all the agents tested against both S. aureus and S. epidermidis. Among the penicillins, cloxacillin, dicloxacillin, and nafcillin were most active, although benzylpenicillin and phenoxymethyl penicillin were more active against susceptible strains. Cephaloridine was the most active of the cephalosporins, and sisomicin was the most active aminoglycoside. Minocycline was more active than the other tetracycline analogues tested. Among the macrolide-lincomycin compounds in clinical use, clindamycin was more active, and lincomycin was less active than erythromycin. The synergy of trimethoprimsulfamethoxazole was more striking against S. aureus than against S. epidermidis. The median minimal inhibitory concentrations of the penicillins, cephalosporins, and aminoglycosides were lower against S. aureus, whereas the minimal inhibitory concentrations of the tetracyclines were lower against S. epidermidis.
A large number of new natural and semisynthetic antibiotics with anti-staphylococcal activity have been introduced recently. This study was performed to compare their activities with those of other compounds that have been available for several or more years. The desirability of having comparative data on the same organisms from one laboratory, obtained by a uniform method, is obvious.
Tests were performed on both Staphylococcus aureus and Staphylococcus epidermidis for the purpose of observing possible differences, and also to obtain information that would be potentially useful in clinical medicine.
MATERIALS AND METHODS
Sixty-five antimicrobial preparations and two of them in combination (trimethoprim plus sulfamethoxazole in a ratio of 1:16; this was selected for convenience of making dilutions for the test -a ratio of 1:20, which has been suggested as the trimethoprim/sulfamethoxazole ratio in blood, might have been used, but no great differences in results were anticipated by using 1:16) were tested for antibacterial activity against 36 strains of S. aureus and 35 strains of S. epidermidis (in several instances, only 12 strains of S. aureus and 12 or 32 strains of S. epidermidis were tested). The antimi-1 Present address: Mayo Memorial Building, University of Minnesota Medical School, Minneapolis, Minn. 55455. crobial preparations tested are listed along with their respective suppliers in Tables 1 through 3; also shown in these tables are the abbreviations for each compound, as used in the figures.
The organisms tested were all recent clinical isolates at Boston City Hospital, provided by A. Kathleen Daly and Alice McDonald, and identified on the basis of colonial morphology, Gram stain, coagulase reaction, and mannitol fermentation tests. The susceptibility testing was done by the agar dilution method using Mueller-Hinton agar and the inocula replicator of Steers et al. (8) , using as inoculum dilutions of overnight cultures. Plates were read for inhibition of growth after 18 h of incubation at 37 C and compared with a refrigerated, inoculated control (for no growth). All organisms were found to be susceptible to methicillin on the basis of 48 h of incubation at 30 C.
RESULTS
The range and median minimum inhibitory concentrations (MICs) of each antibiotic are shown in Tables 1 through 3 , and the cumulative percentages of isolates inhibited at various concentrations of antibiotic are graphed in Fig.  1 through 10 .
Among the penicillins, it is quite obvious that the penicillin nucleus, 6-APA, was much less active than any of the natural or semisynthetic penicillins against both S. aureus and S. ,ug/ml for penicillin G and penicillin V, 0.09 ,ug/ml for ampicillin and epicillin, 0.19 ,ug/ml for amoxicillin, and 0.78 ,ug/ml for carbenicillin and ticarcillin.) Cloxacillin, dicloxacillin, and nafcillin inhibited all of the strains in concentrations of 0.4 ug/ml or less. Aside from 6-APA, ticarcillin and carbenicillin were the least active against S. aureus.
The susceptibility of S. epidermidis to these 16 penicillins (Fig. 2) resembled that of S. ,ug/ml. Ampicillin was one of the most active against S. epidermidis, but it was one of the least active against S. aureus (Fig. 1) 3 and 4) . The 11 aminoglycosides and 2 polymyxins had similar orders of relative activity against both S. aureus (Fig. 5 ) and S. epidermidis (Fig.  6) Table 2 , which also lists the number of strains tested with each agent.
active than amikacin and kanamycin. Verdamicin, like butirosin, also showed greater activity against S. epidermidis (almost as good as sisomicin) than against S. aureus. Gentamicin was about twice as active against S. aureus as was tobramycin (Table 2 ; Fig. 5 ), but the two antibiotics were nearly equal in activity against S. epidermidis, except for about 20% of the strains, which were more susceptible to tobramycin. As with the penicillins and cephalosporins, MICs of the aminoglycosides were usually lower with S. epidermidis than with S. aureus.
The tetracyclines, unlike the penicillins, cephalosporins, and aminoglycosides, showed higher median MICs with S. epidermidis than with S. aureus ( Table 2) . Minocycline was clearly the most active tetracycline against both S. aureus and S. epidermidis, doxycycline was the second most active, and oxytetracycine was clearly the least active tetracycline against S. aureus (Fig. 7) . Oxytetracycline was also least active against S. epidermidis (Fig. 8) . However, chlortetracycline, demeclocycline, methacycine, and tetracycline were only slightly more active against S. epidermidis than was oxytetracycline. Spectinomycin was clearly less active than all the tetracyclines ( Table 2. U.
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and 8) and less active than chloramphenicol, which was rather uniformly active against all strains of S. aureus and S. epidermidis tested.
The results with lincomycins, erythromycin, rifampin, vancomycin, and some other antibiotics are summarized in Table 3 and Fig. 9 and 10. As with the other groups of antibiotics studied here, the relative activities of antibiotics within a group (even as heterogenous a group as this) were relatively similar against S. aureus and S. epidermidis. Rifampin and DPCL (compound U-24729A, a clindamycin derivative) were clearly the most active antibiotics in this group, and bacitracin, clindamycin sulfoxide, and vancomycin were the least active against both S. aureus and S. epidermidis. Clindamycin was more active than erythromycin and lincomycin, which was the least active of the three against strains of both S. aureus and S. epidermidis. However, with the exception of bacitracin (and all of the lincomycins tested against a few resistant strains of S. epidermidis), all ofthe MIC values were low.
The activities*of trimethoprim, sulfamethoxazole, and both compounds in a 1:16 combination are summarized in Table 3 and the numbers of strains tested with each antibiotic are given in Table 2 . FIG. 9 . Susceptibility ofstrains ofS. aureus to eight lincomycin analogues and to rifampin, erythromycin, vancomycin, and bacitracin. Key to the symbols is given in Table 3 , which also lists the number of strains tested with each antibiotic.
was routinely seen, but this was much more striking with S. aureus (Fig. 3) than with S. epidermidis (Fig. 8) .
DISCUSSION
This study of both new and established antibiotics demonstrates the greath variety of compounds with substantial anti-staphylococcal activity. However, the numerous instances in which very high MICs were required for inhibition of a few strains (even though for most of the strains, low MIC values for a given antibiotic, or group of antibiotics, were required for inhibition) emphasizes the variability in antibiotic susceptibility of staphylococci, and the necessity of determining antibiotic susceptibilities in each patient in clinical medicine, when a significant infection is present.
The numerous instances in which one, or several, antibiotics within a group showed most activity should be helpful in determining which new antibiotics should be more thoroughly studied in a clinical setting. Table 3 , which also lists the number of strains tested with each antibiotic.
Obviously, in vitro activity as studied here is only one factor in determining potential clinical utility. Such problems as rapid emergence of resistance, protein binding, poor results with heavier inocula, pH effect, and toxicity clearly restrict the usefulness of many of these very active compounds; the indicated problems especially apply, respectively, to rifampin (4), isoxazolyl penicillins (5, 9), cephaloridine (6), aminoglycosides (1, 2, 6), and minocycline (10) .
